DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tran, T. H.
Right arrow Articles by Greenblatt, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tran, T. H.
Right arrow Articles by Greenblatt, D. J.

Vol. 30, Issue 12, 1441-1445, December 2002

Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors

Thanh Huu Tran, Lisa L. von Moltke, Karthik Venkatakrishnan, Brian W. Granda, Megan A. Gibbs, R. Scott Obach, Jerold S. Harmatz, and David J. Greenblatt

Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and New England Medical Center, Boston, Massachusetts (T.H.T., L.L.v.M., J.S.H., D.J.G.); and Pfizer Inc., Groton, Connecticut (K.V., M.A.G., R.S.O.)

The effect of microsomal protein concentration on the inhibitory potency of a series of CYP3A inhibitors was assessed in vitro using diazepam 3-hydroxylation (yielding temazepam) as an index of CYP3A activity. With diazepam concentrations fixed at 100 µM, inhibition of temazepam formation by fixed concentrations of ritonavir, ketoconazole, itraconazole, OH-itraconazole, norfluoxetine, and fluvoxamine decreased substantially as active protein concentrations increased from 0.0625 to 3.0 mg/ml. However protein concentration had only a small effect on the inhibitory activity of fluconazole. Equilibrium dialysis indicated extensive microsomal binding of all inhibitors except fluconazole; binding increased with higher protein concentrations. Based on the CYP3A content of liver microsomes, decrements in inhibitory potency of stronger inhibitors (ketoconazole and ritonavir) could be explained by specific binding, whereas nonspecific binding is anticipated to account for the effect on weaker inhibitors (norfluoxetine and fluvoxamine). Thus, microsomal binding (specific, nonspecific, or a combination of both) may have a major effect on estimation of inhibitory potency of P450 inhibitors and may contribute to variations among laboratories. The effect can be minimized by use of the lowest possible microsomal protein concentration for in vitro studies of metabolic inhibition.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
H. Gao, L. Yao, H. W. Mathieu, Y. Zhang, T. S. Maurer, M. D. Troutman, D. O. Scott, R. B. Ruggeri, and J. Lin
In Silico Modeling of Nonspecific Binding to Human Liver Microsomes
Drug Metab. Dispos., October 1, 2008; 36(10): 2130 - 2135.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Nakashima, H. Takama, Y. Ogasawara, T. Kawakami, T. Nishitoba, S. Hoshi, E. Uchida, and H. Tanaka
Effect of Cinacalcet Hydrochloride, a New Calcimimetic Agent, on the Pharmacokinetics of Dextromethorphan: In Vitro and Clinical Studies
J. Clin. Pharmacol., October 1, 2007; 47(10): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Giuliano, M. Jairaj, C. M. Zafiu, and R. Laufer
DIRECT DETERMINATION OF UNBOUND INTRINSIC DRUG CLEARANCE IN THE MICROSOMAL STABILITY ASSAY
Drug Metab. Dispos., September 1, 2005; 33(9): 1319 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Venkatakrishnan and R. S. Obach
IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE
Drug Metab. Dispos., June 1, 2005; 33(6): 845 - 852.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. A Bachmann and J. D Lewis
Predicting Inhibitory Drug-Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants
Ann. Pharmacother., June 1, 2005; 39(6): 1064 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Isoherranen, K. L. Kunze, K. E. Allen, W. L. Nelson, and K. E. Thummel
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Drug Metab. Dispos., October 1, 2004; 32(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. M. Jones, D. Hallifax, and J. B. Houston
QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES
Drug Metab. Dispos., May 1, 2004; 32(5): 572 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. M. Stresser, M. I. Broudy, T. Ho, C. E. Cargill, A. P. Blanchard, R. Sharma, A. A. Dandeneau, J. J. Goodwin, S. D. Turner, J. C. L. Erve, et al.
HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE
Drug Metab. Dispos., January 1, 2004; 32(1): 105 - 112.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.